Lineage Cell Revenue Doubles in Q2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Should l Buy LCTX?
Source: NASDAQ.COM
Financial Performance: Lineage Cell Therapeutics reported a significant increase in GAAP revenue, doubling to $2.8 million in Q2 2025 compared to the previous year, but faced a sharp net loss of $30.5 million due to non-recurring charges, overshadowing operational progress.
Clinical Advancements: The company made strides in its cell therapy programs, particularly OpRegen for vision restoration and OPC1 for spinal cord injury, achieving key clinical milestones while maintaining a strong cash position of $42.3 million to support operations through early 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LCTX
Wall Street analysts forecast LCTX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.770
Low
3.00
Averages
4.50
High
9.00
Current: 1.770
Low
3.00
Averages
4.50
High
9.00
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lineage Cell Therapeutics Q4 2025 Earnings Call Insights
- Extended Cash Runway: Lineage has extended its cash runway to Q2 2028 through recent warrant exercises, which is expected to support planned operations and reflects positive progress in financial management.
- Clinical Research Expansion: The GAlette study has added 10 new clinical sites, significantly up from 8 in the previous 6 months, indicating the company's proactive stance in clinical trial preparations that could facilitate later-stage trials.
- Revenue Growth: Total revenues for Q4 2025 reached $6.6 million, an increase of $3.7 million compared to Q4 2024, primarily driven by higher collaboration revenue from the Roche agreement, showcasing success in partnership development.
- Increased R&D Spending: R&D expenses for the fourth quarter totaled $8.2 million, up $4.8 million year-over-year, demonstrating the company's ongoing investment in technology development, despite an overall net loss of $63.5 million largely due to non-cash charges.
See More
Lineage Cell Therapeutics Q4 Earnings Announcement Scheduled
- Earnings Announcement Date: Lineage Cell Therapeutics is set to announce its Q4 earnings on March 5th after market close, with investors keenly awaiting the latest financial performance to assess future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.04, indicating challenges in profitability that could impact investor confidence and stock performance.
- Revenue Projections: Revenue is expected to be $1.96 million, reflecting a significant year-over-year decline of 32.4%, which highlights competitive pressures and weakened product demand, potentially affecting future liquidity.
- Historical Performance: Over the past two years, LCTX has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, demonstrating relative stability in financial forecasting, which may provide some reassurance to investors.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing
- Market Transformation: The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations (CDMOs) capturing 67.5% market share, marking a transition from boutique R&D to scalable bioprocessing infrastructure that accelerates industry growth.
- Surging Demand: The demand for gene and CAR-T therapies has driven CDMO partnerships to rapidly expand viral vector production and GMP-compliant facilities, overcoming previous bottlenecks that constrained commercial access, significantly enhancing market entry speed.
- Investment Opportunity: The regenerative medicine market is projected to surge from $48.45 billion in 2024 to $403.86 billion by 2032, with cell-based therapies representing the fastest-growing segment, creating an urgent investment window, especially as emerging biotechs trade at steep discounts.
- Technological Innovation: Avant Technologies is advancing cell encapsulation technology through its joint venture Insulinova with SGAustria, aiming to provide effective long-term treatments for diabetes patients globally, addressing the immune rejection of implanted cells, thereby significantly improving patients' quality of life.
See More
Snowflake, Symbotic, and Other Major Stocks Decline in Thursday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures up by approximately 0.1% on Thursday morning.
Snowflake Inc Performance: Snowflake Inc reported third-quarter revenue of $1.21 billion, surpassing analyst expectations, but its shares fell 8.6% in pre-market trading.
Other Stocks Declining: Several other stocks experienced significant declines in pre-market trading, including Net Lease Office Properties down 14.7% and Symbotic Inc down 10.5% following a share offering announcement.
Additional Stock Movements: Other notable declines included Capricor Therapeutics down 8.4% after a previous surge, and ADC Therapeutics down 8.1% after reporting trial data.
See More
Lineage Cell Therapeutics, Inc. (LCTX) Shares Prepared Remarks at H.C. Wainwright's 27th Annual Global Investment Conference
Company Overview: Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing novel cell therapies for neurological and ophthalmic conditions, particularly targeting diseases caused by the loss of specific cell types.
Key Focus Area: The company is currently concentrating on treating dry age-related macular degeneration by manufacturing and delivering retinal pigment epithelium (RPE) cells to restore lost function in affected patients.
See More
Lineage Cell Therapeutics Q4 2025 Earnings Call Insights
- Extended Cash Runway: Lineage has extended its cash runway to Q2 2028 through recent warrant exercises, which is expected to support planned operations and reflects positive progress in financial management.
- Clinical Research Expansion: The GAlette study has added 10 new clinical sites, significantly up from 8 in the previous 6 months, indicating the company's proactive stance in clinical trial preparations that could facilitate later-stage trials.
- Revenue Growth: Total revenues for Q4 2025 reached $6.6 million, an increase of $3.7 million compared to Q4 2024, primarily driven by higher collaboration revenue from the Roche agreement, showcasing success in partnership development.
- Increased R&D Spending: R&D expenses for the fourth quarter totaled $8.2 million, up $4.8 million year-over-year, demonstrating the company's ongoing investment in technology development, despite an overall net loss of $63.5 million largely due to non-cash charges.
See More
Lineage Cell Therapeutics Q4 Earnings Announcement Scheduled
- Earnings Announcement Date: Lineage Cell Therapeutics is set to announce its Q4 earnings on March 5th after market close, with investors keenly awaiting the latest financial performance to assess future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.04, indicating challenges in profitability that could impact investor confidence and stock performance.
- Revenue Projections: Revenue is expected to be $1.96 million, reflecting a significant year-over-year decline of 32.4%, which highlights competitive pressures and weakened product demand, potentially affecting future liquidity.
- Historical Performance: Over the past two years, LCTX has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, demonstrating relative stability in financial forecasting, which may provide some reassurance to investors.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing
- Market Transformation: The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations (CDMOs) capturing 67.5% market share, marking a transition from boutique R&D to scalable bioprocessing infrastructure that accelerates industry growth.
- Surging Demand: The demand for gene and CAR-T therapies has driven CDMO partnerships to rapidly expand viral vector production and GMP-compliant facilities, overcoming previous bottlenecks that constrained commercial access, significantly enhancing market entry speed.
- Investment Opportunity: The regenerative medicine market is projected to surge from $48.45 billion in 2024 to $403.86 billion by 2032, with cell-based therapies representing the fastest-growing segment, creating an urgent investment window, especially as emerging biotechs trade at steep discounts.
- Technological Innovation: Avant Technologies is advancing cell encapsulation technology through its joint venture Insulinova with SGAustria, aiming to provide effective long-term treatments for diabetes patients globally, addressing the immune rejection of implanted cells, thereby significantly improving patients' quality of life.
See More
Snowflake, Symbotic, and Other Major Stocks Decline in Thursday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures up by approximately 0.1% on Thursday morning.
Snowflake Inc Performance: Snowflake Inc reported third-quarter revenue of $1.21 billion, surpassing analyst expectations, but its shares fell 8.6% in pre-market trading.
Other Stocks Declining: Several other stocks experienced significant declines in pre-market trading, including Net Lease Office Properties down 14.7% and Symbotic Inc down 10.5% following a share offering announcement.
Additional Stock Movements: Other notable declines included Capricor Therapeutics down 8.4% after a previous surge, and ADC Therapeutics down 8.1% after reporting trial data.
See More
Lineage Cell Therapeutics, Inc. (LCTX) Shares Prepared Remarks at H.C. Wainwright's 27th Annual Global Investment Conference
Company Overview: Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing novel cell therapies for neurological and ophthalmic conditions, particularly targeting diseases caused by the loss of specific cell types.
Key Focus Area: The company is currently concentrating on treating dry age-related macular degeneration by manufacturing and delivering retinal pigment epithelium (RPE) cells to restore lost function in affected patients.
See More
